Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER IMMUNOTHERAPY

CAR T cells reach clinical milestone in prostate cancer

Nature Medicine volume 28, pages 635–636 (2022)Cite this article

Armored CAR T cells show early signs of clinical activity in patients with castration-resistant prostate cancer, paving the way for further development and optimization.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Mechanism of PSMA-directed, TGF-β-armored CAR T cells in castrate-resistant prostate cancer.

References

  1. Narayan, V. et al. Nat. Med. https://doi.org/10.1038/s41591-022-01726-1 (2022).

    Article  PubMed  Google Scholar 

  2. Rosa, K. OncLive https://www.onclive.com/view/p-psma-101-elicits-encouraging-responses-in-metastatic-castration-resistant-prostate-cancer (September 2021).

  3. Neelapu, S. S. Blood 133, 1799–1800 (2019).

    Article  CAS  PubMed  Google Scholar 

  4. Fabrizio, V. A. et al. Blood Adv. https://doi.org/10.1182/BLOODADVANCES.2021006418 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Dorff, T. B. et al. Clin. Cancer Res. 28, 576–584 (2022).

    Article  CAS  PubMed  Google Scholar 

  6. Stultz, J. & Fong, L. Prostate Cancer Prostatic Dis. 24, 697 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Biasco, L. et al. Nat. Cancer 2, 629–642 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. US Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel (accessed February 2022).

  9. US Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel (accessed February 2022).

  10. Rafiq, S., Hackett, C. S. & Brentjens, R. J. Nat. Rev. Clin. Oncol. 17, 147–167 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  11. Netto, G. J. & Epstein, J. I. in Diagnostic Immunohistochemistry 3rd edn. (ed. Dabbs, D. J.) 593–661 (Elsevier, 2011).

  12. Fan, A. C. & Leppert, J. T. JAMA Netw. Open 2, e199233 (2019).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA

    Nicholas P. Tschernia, Scott M. Norberg & James L. Gulley

Authors
  1. Nicholas P. Tschernia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott M. Norberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James L. Gulley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James L. Gulley.

Ethics declarations

Competing interests

N.P.T., S.M.N. and J.L.G. are employees of the National Cancer Institute, US National Institutes of Health.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tschernia, N.P., Norberg, S.M. & Gulley, J.L. CAR T cells reach clinical milestone in prostate cancer. Nat Med 28, 635–636 (2022). https://doi.org/10.1038/s41591-022-01742-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-022-01742-1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing